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Conclusions:  A non dipping pattern is common in cardiac amyloidosis due 
to FAP (82% of the patients in this series). This pattern is not associated with 
hypertension and is related to low levels of blood pressure during daytime.
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Arterial hypertension (AH) is associated with a cardiovascular remode-
ling in which the Renin-Angiotensin-Aldosterone system plays a central 
role. Studies suggest that in AH the development of cardiac ¿ brosis results 
from an imbalance between pro¿ brotic (CTGF,TGFß) and anti¿ brotic 
(BNP,ANP,BMP4) pathways, and that aldosterone aggravates this imbalance. 
Our aim was to determine, in a context of AH, the role of intracardiac aldos-
terone in the development of myocardial ¿ brosis.
AS-RenTgKC mice were created by crossing strains of mice overexpressing 
the aldosterone synthase (AS) gene in cardiomyocytes with RenTgKC mice ove-
rexpressing the renin gene in liver. AS male mice have an increase (x2) of intra-
cardiac aldosterone and an altered coronary function; RenTgKC mice have an 
8-fold increase of plasmatic renin, increased AngII, and sustained hypertension.
The heterozygous RenTgKC (Ren+/-) as well as the AS-RenTgKC mice 
were hypertensive (139±5 mmHg) compared to WT or AS mice (98±6.5 
mmHg). The echocardiographic data did not reveal major changes of cardiac 
function. The Sirius red staining showed a cardiac ¿ brosis in Ren+/- which 
was more important in perivascular and interstitial area in AS-REN+/- mice 
(P<0.05). The expression of pro¿ brotic factors like CTGF (x1.9;p<0.05) and 
TGF-ß (x1.5;p<0.01) was similarly increased in both Ren+/- and AS-Ren+/- 
mice compared to WT and AS mice, respectively. However, hyperaldostero-
nism combined with AH favored the presence of macrophages (Cd68+ cells) 
and enhanced the transcription of MCP-1 (x1.43;p<0.01) and the expression 
of Galectin-3 (P<0.05) in both perivascular and interstitial area. It is worthy 
to note that the galectin-3 expression was related to the preferential expres-
sion of collagen 1 versus collagen 3 in AS-Ren +/- (x1.7 and x0.8 respecti-
vely). Interestingly enough, the AH-induced increases in mRNA and protein of 
the anti¿ brotic factor BMP4 were signi¿ cantly decreased (-40% and -20% res-
pectively) in AS-Ren+/- mice whereas the expression of both ANP and BNP 
was completely blunted. The MR-antagonist Eplerenone given for 1 week, 
increased the expression of BNP, ANP and BMP4.
These data indicate that in AH, a cardiac hyperaldosteronism through 
MR-dependent speci¿ c pathways worsens the development of myocardial 
¿ brosis through activation of inÀ ammatory process and inhibition of anti¿ -
brotic pathways.
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In healthy volunteers, a cytochrome P450 epoxygenases-related epoxyeico-
satrienoic acids (EETs) pathway maintains basal conduit artery diameter during 
altered NO availability. Whether this compensatory mechanism is ef¿ cient 
during essential hypertension is unknown. Radial artery diameter and blood 
À ow were measured in 14 non-treated essential hypertensive patients and 14 
normotensive control subjects during brachial infusion for 8 min of inhibi-
tors of NO-synthase (NG-monomethyl-L-arginine, L-NMMA: 8 mol/min) 
and cytochrome P450 epoxygenases (À uconazole: 0.4 mol/min) alone and in 
combination. Local blood samples were drawn to quantify the plasma level of 
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Introduction: Cardiac amyloidosis due to familial amyloid polyneuropathy 
(FAP) displays myocardial in¿ ltration, conduction disorders and cardiac den-
nervation. However dipping status measured by APBM is unknown in cardiac 
amyloidosis.
Methods & Results: Thirty four patients with proven FAP underwent 
ABPM. Results were compared with 38 control patients without hyper-
tension (cf. table). The two groups displayed similar age and sex ratio. 
In FAP group, cardiac in¿ ltration was documented in 70% by echocardio-
graphy and a restrictive pattern was documented in 29% on catheterism. No 
hypertension was documented in the FAP group. A non dipping pattern was 
documented in 28/34 (82%) in FAP vs. 21/38 (55%) in the control group 
(P=0.027). Blood pressure levels were signi¿ cantly lower during daytime 
in the FAP group.   Severity of cardiac amyloidosis assessed by echocardio-
graphy and catheterism was not associated with the blood pressure pro¿ le.
FAP group Control group P
Total
SBP (mmHg) 114 ± 12 120 ± 7 0,013
DBP (mmHg) 71 ± 8 74 ± 8 0,07
MBP (mmHg) 86 ± 8 87 ± 7 0,02
HR (bpm) 73 ± 12 71 ± 9 0,7
Dipping SBP (%) 3,1 ± 7,2 7,4 ± 7 0,01
Dipping DPB (%) 5,5 ± 8,5 14,1 ± 9 <0.0001
Dipping MBP (%) 4,8 ± 7,5 11,1 ± 8 0,002
Daytime
SBP d (mmHg) 115 ± 13 123 ± 7 0,004
DBP d (mmHg) 72 ± 9 77 ± 9 0,02
MBP d (mmHg) 87 ± 9 93 ± 8 0,006
HR d (bpm) 74 ± 13 74 ± 9 0,8
Nightime
SBP n (mmHg) 111 ± 12 114 ± 9 0,2
DBP n (mmHg) 68 ± 8 66 ± 7 0,4
MBP n (mmHg) 83 ± 8 83 ± 7 0,9
HR n (bpm) 70 ± 11 66 ± 10 0,1
Table. SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean 
blood pressure: HR: heart rate; bpm.: beat per minute. 
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Objective: Extramel® (EM) was previously shown to prevent obesity and 
atherosclerosis in hamster models, through a reduction in oxidative stress 
(Decorde, J.A.F.C., 2009). Moreover, an inhibitory effect of the conversion of 
angiotensin I (AngI) was observed in vitro with EM.
The aim of the study was to evaluate the inÀ uence of EM supplementation on 
arterial pressure, cardiac mass and cardiac superoxide dismutase (SOD) in SHR.
Methods: Seventy two 9 week-old SHR were divided in 4 groups (n=18 
in each). Two groups received EM at 4 or 40 units of SOD per day. A group 
received the angiotensin I-converting enzyme (ACE) inhibitor, enalapril at the 
daily dose of 30mg.kg-1, and a group of untreated SHR served as controls.
Tail-cuff pressure (TCP) was measured in all rats before and after 2, 7, 14, 
21 and 28 days of treatment.
The heart and the left ventricle were removed and weighed, and cardio-
myocyte diameter was measured by microscopy after 4, 14 and 28 days (n=6).
The pressor response to AngI (50 ng iv) was determined after 4 days of 
treatment.
After 28 days of treatment, NF-NB hepatic activity was determined and 
cardiac SOD was quanti¿ ed by western blot.
Results: Tail-cuff pressure remained stable in untreated SHR while it 
decreased by 10% from the second day to the end in EM 4U and 40U groups.
Left ventricular mass index and cardiomyocyte diameter was reduced by 
EM 4U and 40U.
EM did not affect the response to AngI whereas it was inhibited by 50% in 
enalapril-treated SHR.
The 2 doses of EM increased (by 30%) the cardiac quantity of SOD after 
28 days.
Enalapril had a more potent effect of TCP and cardiac mass but it was 
devoid of inÀ uence on cardiac SOD.
None of the treatments affected hepatic NF-NB activity.
Conclusion: EM lowers hypertension and reduces left ventricular hyper-
trophy in SHR. These bene¿ cial effects do not seem to be linked to ACE 
inhibition, but rather related to better antioxidant defense as suggested by the 
higher concentration of SOD in the heart.
SHR Untreated Enalapril EM 4U EM 40U
TCP (mmHg)
basal 197±3 192±4 190±2 200±4
after 2 days 199±6 171±7* 183±3 193±5
after 14 days 204±4 149±3* 183±2* 187±4*
after 28 days 198±5 143±3* 180±5* 179±4*
Final values
Body weight (g) 299±7 306±3 301±5 282±4
Left ventricular mass 
index (mg/g)
2.6±0.04 2.0±0.04* 2.4±0.04* 2.5±0.04*
Cardionomyocyte dia-
meter (Pm)
25±0.7 17±0.3* 17±1.0* 19±1.4*
Quantity of cardiac 
SOD (%)
100±0 78±9 135±19* 132±16*
nitrites (indicator of NO availability) and EETs using a tri-iodide/ozone-based 
chemiluminescence assay and gas chromatography-mass spectrometry respec-
tively. L-NMMA reduced radial artery diameter in controls (-0.037±0.010 mm) 
and, to a larger extent, in patients (-0.091±0.008 mm) with similar decreases 
in blood À ow. Fluconazole reduced radial diameter in controls (-0.034±0.012 
mm) but not in patients (0.010±0.014 mm) without affecting blood À ow. 
L-NMMA+À uconazole reduced radial diameter in controls (-0.137±0.011 mm) 
and, to a lesser extent, in patients (-0.086±0.011 mm) with similar decreases 
in blood À ow. This decrease in higher was higher than during L-NMMA and 
À uconazole alone in controls, but was similar than during L-NMMA alone in 
patients. Local plasma nitrite and EETs level were reduced in both groups by 
L-NMMA and À uconazole respectively. Endothelium-independent dilatation to 
sodium nitroprusside was similar between groups. These results show that the 
role of EETs in the maintain of conduit artery diameter under basal condi-
tions and altered NO availability is impaired in essential hypertensive patients. 
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Purpose: In hypertension, left ventricle (LV) hypertrophy (LVH) is a 
potent prognostic factor to predict outcome. New techniques for analyzing 
blood metabolites pro¿ les, such as high resolution Proton Nuclear Magnetic 
Resonance (1H NMR) spectroscopy, have emerged. 1H NMR has proved to be 
one of the most powerful technologies in metabonomic studies of bioÀ uids. 
We investigated for plasma LVH biomarkers in human Hypertensive Heart 
Disease.
Methods: 96 hypertensive patients (48 LV remodeling vs. 48 normal LV 
size) were selected from 2007 to 2009 for plasma 1H NMR-based metabo-
nomic pro¿ ling. A multivariate statistical analysis of the spectral data set was 
performed by using the Partial Least Squares Discriminant Analysis (PLS-DA).
Results: PLS-DA Scores plot of spectral data revealed sample clustering 
according to the clinical state. PLS-DA loading plot reveals the variables 
inÀ uencing that discrimination. Thus, discriminant variables were identi¿ ed as 
signals coming from the methylene (-CH2) and methyl (-CH3) moieties of ali-
phatic chain from plasma lipids. Furthermore, the CH2/CH3 ratio which is an 
indicator of mean length of the aliphatic lipid chain was signi¿ cantly higher 
for the LVH group of patients (¿ g.1).
Discussion: CH2/CH3 ratio which is representative of the length of aliphatic 
lipids chains in plasma was signi¿ cantly increased in blood from patients with 
LV remodeling that would indicate metabolic consequences of LVH.
Conclusion: In hypertension, LVH was signi¿ cantly correlated to an 
increase of the mean length of aliphatic lipids chains in plasma.
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weak individually). Focusing on clinical CV variables (BP, RAS…) that have 
been shown to be genetically inÀ uenced, we are establishing an analysis of 
model parameters and variables (PV) as they interact to yield given values 
of CV variables. We present the exploratory sensitivity analysis of the 1992 
version (unpublished) of the Guyton model, by statistically screening the indi-
vidual and combined inÀ uences of model PV on BP (Morris, 1991). Screening 
114 parameters yielded about 100,000 ‘virtual subject’ cases, from which 
close to 5% exhibited steady-state BP > 140 mmHg. Generated data are cur-
rently being analyzed to extract the most signi¿ cant features controlling BP/
HBP and to confront them to polymorphisms and clinical knowledge.
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Nt-ProBNP as a predictor of mortality in hypertension
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N-terminal pro brain natriuretic peptide (NT-proBNP) is a validated marker 
of risk in heart failure and in acute coronary syndrome. In hypertension, 
NT-proBNP is related to left ventricular hypertrophy (LVH) and has even been 
proposed as a diagnostic test for this condition. On the contrary, very few data 
are available concerning its prognostic value beyond traditional risk factors.
Thus, the present study aimed at examining the relation of NT-proBNP with 
total mortality. In 691 consecutive hypertensive patients free of heart failure, 
referred to our department for hypertension work-up (47% women, mean 
age±SD, 52±14 yrs, 24-hour systolic BP, 152±21 mmHg, 15% with LVH by 
EKG), NT-proBNP was measured (232±804 pg/ml) and analysed after divi-
ding by tertiles of NT-proBNP: Tertile 1 (<50.8 pg/ml); Tertile 2 (50.8 - 132 
pg/ml); Tertile 3 (>132 pg/ml) or according to a threshold used for LVH dia-
gnosis (111pg/mL for men and 144pg/mL for women). Mortality was assessed 
through a questionnaire and through the of¿ ce of Civil registration after a 
mean duration of 5.7 years till death or censoring date. During that period, 40 
deaths occurred. The ¿ gure shows the Kaplan-Meier survival curves for the 3 
tertiles. Of note is the signi¿ cantly poorer prognosis attached to Tertile 2 rela-
tive to Tertile 1 (log-rank test, p=0.037), Tertile 3 relative to Tertile 2 (log-rank 
test, p=0.013) and Tertile 3 relative to Tertile 1 (log-rank test, p<0.001). The 
result is similar for the division into two groups (log rank test, p<0.001). In a 
Cox analysis including age, 24-hour systolic BP, diabetes, smoking, hypercho-
lesterolemia as potential confounders, the NT-proBNP retained a signi¿ cant 
independent prognostic value (p<0.01). Adding proteinuria and Sokolov index 
to the model did not change the results.
Based on these results, NT-proBNP appears as a valuable prognostic marker 
in hypertension and should be used as a simple tool for risk strati¿ cation.
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 A few experimental rat models of short-term variability are well characte-
rized but none is available to characterise the impact of long term blood À ow 
amplitude on end-organ damage (EOD). Our aim is to develop a new experi-
mental rat model by evaluating chronical long-term arterial pressure variations 
inherent to a discontinued anti-hypertensive therapy in spontaneously hyper-
tensive rats (SHR). Thirty-eight SHR were divided into 3 groups treated for 8 
weeks by placebo (PT) or by valsartan (30 mg/kg, po) daily (CT) or every 3 
days (DT). Five rats of each group were fully investigated by radiotelemetry 
3 days a week during all the experiments. Long term SBP variation was ana-
lyzed using Chronos¿ t® and short term variability by spectral analysis. For 
the other 8 rats of each group, EOD was evaluated by pulse wave velocity 
(PWV) and cardiac hypertrophy measurements. Systolic blood pressure (SBP) 
was equally reduced in DT (138±3 mmHg) and CT (137±1 mmHg) compared 
to PT (160±2 mmHg) at the end of the study (p<0.01). In accordance with the 
SBP decrease, the sympathetic tone was lower in the treated groups compared 
to PT. The 3 days SPB amplitude was 15.3±0.8 mmHg in PT and 12.9±1.1 
mmHg in CT but increased in DT (16.5±0.8 mmHg, p<0.01 with CT). PWV 
(DT: 759±31cm/s, PT: 935±103 cm/s, CT: 679±24 cm/s) and heart weight 
were signi¿ cantly higher in DT and PT (DT: 1.51±0.03 g, PT: 1.50±0.03 g) 
compared to CT (1.42±0.02 g). Our results demonstrate that a chronically DT 
with valsartan is able to reduce SBP in the same extent as CT. Nevertheless, 
DT is associated with an enhancement of its amplitude. The increased arterial 
stiffness and cardiac hypertrophy indicate that a DT may not achieve the car-
diovascular bene¿ ts of a CT suggesting that this experimental model is inte-
resting to investigate the impact of long term blood À ow variations on EOD.
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Cardiovascular disease (CVD) and high blood pressure (HBP) are major 
causes of death. Involving multiple factors, their complexity translates into cli-
nical and therapeutic variability and impeded ef¿ cacy of treatment. Modeling 
and simulation has emerged as a necessary tool for the (i) integration of 
knowledge into realistic models and (ii) in silico exploration of scenarios. 
Guyton’s systems model of circulation has led to the physiological integra-
tion of the main CVR components into a dynamic model of BP regulation 
(PCM, Physiological Circulatory Model) (Guyton et al, 1972). The SAPHIR 
project updated PCM with more realistic features, including a pulsatile heart 
and an endocrine renin-angiotensin system (Thomas et al, 2008; Hernandez et 
al, 2009; Guillaud et Hannaert, 2010); this is a basis for the BIMBO project, 
which target better assessment of CV risk through the creation of a virtual 
population of HBP patients. However, PCM is still ‘generic’ and incomplete 
(e.g., no subcellular level): it is our ambition to progressively ¿ ll gaps in PCM 
to address patient-speci¿ c etio-therapeutic issues. Among variability sources, 
polymorphisms exert non-linear, strongly interdependent inÀ uences (often 
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Methodology/Principal Findings: Experiments were performed, ex 
vivo, on human uterine artery samples obtained after hysterectomy. We 
studied variations in isometric tension of arterial rings in response to 
the vasoconstrictor ET-1 and evaluated the effects of various vasodila-
tors and ET-receptor antagonists on this response. Among antihyperten-
sive drugs, only dihydropyridines were effective in blocking and reversing 
the ET-1 contractile response. Their efficiency, independent of the concen-
tration of ET-1, was only partial. Hydralazine, alpha-methyldopa and labe-
talol had no effect on ET-1 induced contraction which is mediated by 
both ETA and ETB receptors in uterine artery. ET receptors antagonists, 
BQ-123 and BQ-788, slightly reduced the amplitude of the response to 
ET-1. Combination of both antagonists was more efficient, but it was not 
possible to reverse the maximal ET-1-induced contraction with antagonists 
used alone or in combination.
Conclusion: Pharmacological drugs currently used in the context of PE, do 
not reverse ET-1 induced contraction.  Only dihydropyridines, which partially 
relax uterine artery previously contracted with ET-1, might offer interesting 
perspectives to improve placental perfusion.
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Management of Hypertension in pregnancy: lessons from Endothelin-
dependent vasoconstriction in human uterine artery
Clotilde Dechanet [Orateur] (1), Aurelie Fort (1), Elisabet Barbero-
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(1) INSERM U1046, Montpellier, France – (2) Université Montpellier I, 
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Background: Preeclampsia (PE) is a pregnancy-speci¿ c vasoconstrictive 
disorder, characterized by the development of hypertension and proteinuria after 20 
weeks of gestation in previously normotensive, non-proteinuric women. Reduced 
uteroplacental perfusion, the initiating event in PE, is associated with enhanced 
endothelin-1 (ET-1) production which feeds the vasoconstriction of uterine artery. 
Whether the treatments of PE were effective on ET-1 induced contraction and 
could reverse placental ischemia is the question addressed in this study. We inves-
tigated the effect of antihypertensive drugs used in PE and of ET receptor antago-
nists on the contractile response to ET-1 in human uterine arteries.
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